23:07 , May 14, 2019 |  BC Extra  |  Company News

Management tracks: DBV, Beam, Aeon Biopharma

DBV Technologies S.A. (Euronext:DBV; NASDAQ:DBVT) said Deputy CEO and Principal Financial Officer David Schilansky will leave the company in August to pursue other opportunities. The allergy company is searching for a new CFO but will...
00:50 , Jan 5, 2019 |  BC Extra  |  Company News

Flurry of management moves on eve of JPM

More than 30 biopharma companies announced executive changes to kick off the New Year, including Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) and Immunocore Ltd. (Abingdon, U.K.), both of which brought on former AstraZeneca plc (LSE:AZN; NYSE:AZN) executives...
23:44 , Jun 22, 2018 |  BC Extra  |  Company News

Roche taps gRED’s Sabry as global head of partnering

A newly created global head of partnering role at Roche (SIX:ROG; OTCQX:RHHBY) is set to combine the pharma’s partnering functions for the first time since it completed its acquisition of Genentech Inc. James Sabry, head...
23:27 , May 1, 2018 |  BC Innovations  |  Distillery Therapeutics

Autoimmune disease

INDICATION: Inflammatory bowel disease (IBD) Mouse studies identified a peptide-based GLP-2R activator that could help treat IBD. Chemical synthesis and testing in a cell-based activity assay of GLP-2-based stapled peptides yielded a peptide that activated...
20:32 , Mar 5, 2018 |  BC Week In Review  |  Company News

Celgene licenses drug modifying tech from Amunix

Amunix Operating Inc. (Mountain View, Calif.) licensed its XTEN and ProTIA technologies to Celgene Corp. (NASDAQ:CELG) to discover and develop drugs against unspecified targets. Amunix told BioCentury that the technology is exclusive for Celgene's undisclosed...
01:40 , Jan 27, 2018 |  BioCentury  |  Strategy

Growing up Genzyme

The proposed acquisition of Bioverativ Inc. ticks multiple boxes on Sanofi’s to-do list for transforming itself into a top tier pharma, and solidifies the position of its Genzyme unit as the pharma’s growth engine. Olivier...
21:19 , Sep 22, 2017 |  BC Extra  |  Financial News

Versartis plummets on Phase III GHD miss

Versartis Inc. (NASDAQ:VSAR) lost $18.93 (88%) to $2.67 on Friday after announcing after market close Thursday that somavaratan (VRS-317) missed the primary endpoint in the Phase III VELOCITY trial to treat pediatric growth hormone deficiency...
19:54 , Sep 22, 2017 |  BC Week In Review  |  Clinical News

Versartis' somavaratan misses in Phase III for pediatric GHD

Versartis Inc. (NASDAQ:VSAR) said somavaratan (VRS-317) missed the primary endpoint of non-inferiority to Genotropin somatropin in the Phase III VELOCITY trial to treat pediatric growth hormone deficiency (GHD). In the intent-to-treat (ITT) population, twice-monthly subcutaneous...
00:19 , Sep 22, 2017 |  BC Extra  |  Clinical News

Versartis falls on Phase III GHD miss

Versartis Inc. (NASDAQ:VSAR) plummeted $18.20 (84%) to $3.40 in after-hours trading Thursday after reporting that somavaratan (VRS-317) missed the primary endpoint of non-inferiority to Genotropin somatropin in the Phase III VELOCITY trial to treat pediatric...
00:20 , Jul 8, 2017 |  BioCentury  |  Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...